Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand

Summary

This study assesses the effectiveness of reactive focal mass drug administration (rfMDA), targeting both village and forest working populations, compared to control for reducing the health promotion hospital-level (sub-district) incidence and prevalence of P. falciparum and P. vivax within five provinces in Thailand.

Conditions

• Plasmodium Falciparum Malaria
• Plasmodium Vivax Malaria

Interventions

OTHER

Case Management and Follow-up

Individuals will be told of their test result and a positive test result on either RDT will prompt treatment as per the national treatment guidelines. * Individuals with P. falciparum infection will be treated with an age-appropriate course of dihydroartemisinin/piperaquine (DHAP) or artesunate-pyronaridine (Pyramax) and PQ. * At all study sites in Thailand, patients with a P. vivax infection identified by the standard combination RDT will be tested by the VMV and Health Promotion Hospital (HPH) staff member using the quantitative G6PD RDT. G6PD normal individuals will be treated with Chloroquine (CQ) and a 14-day course of primaquine (PQ). G6PD deficient individuals will receive CQ alone and referred to the nearest health facility for further primaquine management decisions.

OTHER

Reactive focal mass drug administration (rfMDA)

Reactive focal mass administration (rfMDA) will be implemented around the index case household and to forest co-workers/co-travelers in Thailand. The VMV will conduct the investigation visit within 7 days after the notification of the index case. All members of the index case's household as well as all members of the nearest five households around the index case's household, including temporary visitors will be invited to participate in the study and to be treated for malaria without a malaria test. After obtaining participants' or parents/guardians' consent, the VMV will proceed with the participant questionnaire, and all consenting household members will be tested for G6PD using the G6PD quantitative test prior to administration of antimalarials. For rfMDA, all eligible participants will be offered artesunate-mefloquine (AS-MQ). Per national policy, a 14-day course of primaquine will be administered to G6PD non-deficient study participants.

Sponsors & Collaborators

• Center for Malariology, Parasitology, and Entomology

  collaborator UNKNOWN

• Tulane University School of Public Health and Tropical Medicine

  collaborator OTHER

• University of Massachusetts, Amherst

  collaborator OTHER

• Centers for Disease Control and Prevention

  collaborator FED

• University of California, San Francisco

  lead OTHER

Principal Investigators

• Adam Bennett, MA, PhD · University of California, San Francisco

• Cheewanan Lertpiriyasuwat, MD · Ministry of Health, Thailand

Study Design

Allocation

RANDOMIZED

Purpose

SCREENING

Masking

NONE

Model

FACTORIAL

Eligibility

Min Age

18 Months

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2020-11-01

Primary Completion

2022-03-31

Completion

2022-03-31

Countries

• Thailand

Study Locations